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An epidural abscess is a localized collection of purulent fluid between the dura mater
and the overlying vertebral column (spinal epidural abscess) or skull (intracranial epidural
abscess).1,2 Early diagnosis of epidural abscess is essential as without timely intervention
neurologic injury with permanent sequelae can develop.3

SPINAL EPIDURAL ABSCESS
Epidemiology
Spinal epidural abscess (SEA) is more common than intracranial epidural abscess and
is increasing in incidence. In 1975 the reported incidence of SEA was 0.2-2 per 10,000
hospitalized patients. Over the past four decades this has risen to 10-12 per 10,000
hospitalized patients in some referral centers.4–6
This increase is likely due to a rising number of patients with risk factors for SEA
including intravenous drug use (IVDU), diabetes mellitus, advanced age, renal failure,
and compromised immunity as well as degenerative spinal column disease and the
growing use of therapeutic spinal interventions including instrumentation, injections,
catheter placement and anesthetic procedures.7,8 The ongoing opioid epidemic in
the United States has had a particular impact on the increased incidence of SEA given
the risks of endovascular infection and metastatic seeding associated with intravenous drug use.9 The clinical utility of associated risk factors in the diagnosis of SEA in
unclear, however, given their apparent absence in 20-50% of patients.10 Detection of
SEA with the wide-spread availability of sensitive imaging modalities such as magnetic
resonance imaging (MRI) has also improved diagnostic accuracy in recent decades.8

Pathophysiology
One-half of SEA infections are caused by hematogenous spread from a remote site
of infection. Common sources include the skin, urinary tract, oral cavity, infection
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* Estimates from the original published data by Lee TH et al. Derivation and prospective validation of a simple index
for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999 Sep 7; 100(10):1043-9
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Contiguous extension of infection from
osteomyelitis in an adjacent vertebral
body or from a psoas or retropharyngeal
muscle abscess or decubitus ulcer is estimated to account for up to one-third of
infections. 3,11 Vertebral body infection
usually results from hematogenous
seeding of the adjacent avascular disc
space.12,14
Direct inoculation of the epidural space
from spinal surgery, injection or catheter
placement is another route of infection.
Infection can be acquired during the
procedure itself or from ascending microorganisms from the skin when a device
is retained.5,15,16 Additionally, a hematoma
secondary to osseous or ligamentous
injury can become seeded by bacteria
leading to SEA formation.5 In up to 30%
of patients no source is identified.5,17,18

Neurologic impairment resulting from
SEA is usually the result of spinal cord
compression by the infected mass
with possible contribution of vascular
occlusion.19
Clinical presentation

Table 1. Symptoms of Epidural Abscess at Different Stages [adopted from (20).
Symptom

of an indwelling vascular access and
endocarditis.3,5,11,12 Several regions of the
spine may be involved in hematogenous
infection. Hematogenous spread via the
pelvic cavity’s venous drainage system
which connects with those of the spine
forming Batson’s plexus may facilitate
infection from a urinary source.13

R isk estimates from Duceppe et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk
Assessment and Mamagement for Patients Who Undergo Noncardiac Surgery. These estimates were based on
external validations published after the original study by Lee TH et al (1999).

Four stages of disease severity have been
recognized in patients presenting with
SEA. 20 (Table 1) Presentation in stages I
or II is more common, while greater
residual deficit is found in those
presenting in stages III or IV. Fever is
present in 50-60% of patients while the
classic triad of fever, back pain and
neurologic deficits is seen in only a
minority. 21–23 Back pain, present in 95%
of patients, with associated nerve root
pain, radiculopathy and paresthesia may
be the worst of a patient’s life, distinct
from chronic back pain. Depending on
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Physical examination findings include
spinal tenderness in up to 75% of patients
which can be focal or diffuse. Neurologic
deficits including spinal cord dysfunction with motor weakness, sensory loss,
sphincter dysfunction and paralysis may
be found in advanced stage presentation. Once paralysis develops (stage
IV), it quickly becomes irreversible,
emphasizing the critical need for timely
diagnosis.5,18,24

Diagnosis

Figure 1a.
T1-weighted axial MRI image showing
a left occipital region epidural and
extracranial fluid collection/abscess.
Reprinted with permission from Priolo SM et al.
Acupuncture induced cranial epidural abscess.
World Neurosurg 2019 May;125:519-526.

The diagnosis of SEA may be delayed
with up to 75% of cases misdiagnosed on
first presentation. Back pain, with a wide
differential diagnosis, may be attributed
to arthritis or muscular pain.7,10 Patients
presenting with sepsis and/or altered
mental status may be unable to provide
a history. 25 One series looking at 63
patients found that a correct diagnosis of
SEA was made after 2 emergency room
visits in 51% of cases , while a further
11% were identified on a third visit. This
is significant as residual motor weakness
was identified in up to 45% of the cohort
who experienced delays vs 13% of those
who did not. 22 The increased incidence
of SEA has not impacted this diagnostic
delay.6,21 Recognition of SEA prior to the
onset of neurologic symptoms is critical
in patients who present with back pain.
Diagnosis should be suspected based
on clinical presentation and supported
with testing. Definitive diagnosis of SEA
requires drainage and culture. 2

Laboratory Testing
Inflammatory markers including
C-reactive protein (CRP) and erythrocyte

sedimentation rate(ESR) are sensitive tests
for the diagnosis of SEA and are usually
elevated with an ESR >20 mm/h reportedly
found in 95% of cases. Leukocytosis is also
common, reported in 60-80% of cases.
These tests are not specific for SEA.5,10,26
Blood cultures should be obtained and
may be positive in up to 60% of cases.22,27

Imaging Studies
MRI with gadolinium is the imaging study of
choice with a high sensitivity and specificity
for detection of SEA (Figure 1b). Imaging the
entire spine to exclude noncontiguous SEA
is recommended.28 MRI is also the study of
choice for detection of vertebral osteomyelitis and/or discitis in patients presenting
with back pain.18,29 Comparison of T1 and
T2 weighted contrast enhanced images is
used in anatomic localization of SEA and
to define the extent of infection including
assessment for multi-level involvement.30
Computed tomography (CT) with
intravenous contrast is an alternative
diagnostic imaging study with lower
sensitivity and specificity than MRI. 18
Myelography followed by CT scan is a
highly sensitive study although an invasive procedure requiring exposure to
ionizing radiation with a lower specificity
than MRI. Myelography is usually reserved
for patients who cannot undergo MRI.
Spinal puncture for myelography should
be performed distant from the area of
suspected infection.5,17,18 Echocardiography is indicated in all cases of epidural
abscess to exclude endocarditis.

Microbiology
Pathogen identification is very important

Table 2. Pathogens in Spinal Epidural Abscess
Pathogen
Figure 1b.

Staphylococcus aureus

60–90

Saggital T2 weighted MR image of the
thoracic spine showing a mid-thoracic
dorsal epidural abscess.

Gram-negative bacilli

10–15

Streptococcus species

10

Coagulase-negative staphylococci

3–6

Enterococci

1–2

Fungi

1–2

Anaerobes

1–2

the spine level, pain can radiate to the
abdomen, chest or neck, mimicking
other conditions.5,18 Focal weakness in
either the upper or lower extremities is
present in 40% of patients and neurologic deterioration may develop within
hours to days or over weeks to
months.10,11,18,24

10

Percent %
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Mycobacteria

<1

Polymicrobi

5–10

Based on references 1, 3–7, 15, 17, 18, 22, 23,25
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Table 3. Antimicrobial Therapy for Epidural Abscess of the Central Nervous System
Microorganism

First Choice

Alternatives for Anaphylactic Allergy or Resistance.

Staphylococci, oxaclllln susceptible

nafcillin or oxacillin 2 g IV q4-6 h; consider adding
rifampin 600 mg PO q24 h if retained hardware

cefazolin 2g IV q8 h, vancomycin 15-20 mg/kg IV q12 h or
daptomycin 6-8 mg/kg IV q24 h or linezolid 600 mg PO/IV
q12 h; consider adding rifampin 600 mg PO q24 h if retained
hardware

Staphylococci, oxacillin resistant

vancomycin 15-20 mg/kg IV q12 h, consider adding
rifampin 600 mg PO q24 h if retained hardware

daptomycin 6-8 mg/kg IV q24 h or linezolid 600 mg PO/
IV q12 h or trimethoprim-sulfamethoxazole 5mg/kg IV/
PO q8-12 h, consider adding rifampin 600 mg PO q24 h if
retained hardware

Streptococci, confirm susceptlblllty
testing for vlrldans streptococci

penicillin G 18-24 million units IV q24 h continuously
or in 6 divided doses, or ceftriaxone 2g q 12-24 h

vancomycin 15-20 mg/kg IV q12 h

Enterococci, penicillin susceptible

penicillin G 20-24 million units IV q24 h continuously
or in 6 divided doses, or ampicillin sodium 12g IV q24
h continuouslv or in 6 divided doses

vancomycin 15-20 mg/kg IV q12 h or daptomycin 6-8 mg/kg
IV q24 h or linezolid 600mg PO/IV q12 h

Enterococcl, penicillin resistant

vancomycin 15-20 mg/kg IV q12 h

daptomycin 8-10 mg/kg IV q24 h or linezolid 600 mg PO/
IV q12 h

Enterococci, vancomycin resistant

daptomycin 10-12 mg/kg IV q24 h

Linezolid 600 mg PO/IV q12 h

Cutibacterium acnes

penicillin G 20 million units IV q24 h continuously or in
6 divided doses, or ceftriaxone 2g q12-24 h

vancomycin 15-20 mg/kg IV q 12 h or daptomycin 6-8 mg/
kg IV q24 h or clindamycin 600-900 mg IV q8 h

Enterobacteriaceae, confirm
susceptibility testing

ceftriaxone 2g q 12-24 h or cefepime 2g IV q8 h or
ertapenem 1 g IV q24 h

meropenem 1-2g q8 h or ciprofloxacin 400 mg IV q12 h(or
500 mg PO q12 h) or trimethoprim-sulfamethoxazole 5mg/
kg IV/PO q8-12 h

Enterobacteriaceae, confirm
susceptibility testing

ceftriaxone 2g q 12-24 h or cefepime 2g IV q8 h or
ertapenem 1 g IV q24 h

meropenem 1-2g q8 h or ciprofloxacin 400 mg IV q12 h(or
500 mg PO q12 h) or trimethoprim-sulfamethoxazole 5mg/
kg IV/PO q8-12 h

Pseudomonas species, confirm
susceptibility testina

cefepime 2 g q8 h, ceftazidime 2 g q8 h or
meropenem 1-2 g q8 h

azactam 2 g q8 h or ciprofloxacin 400 mg IV q8 h (or 750 mg
PO q12 h)

Acinetobacter species, confirm
susceptibility testina

meropenem 1-2 g IV q8 h

ciprofloxacin 400 mg IV q12 h (or 500 mg PO q12 h) or
ampicillin- sulbactam 3g/1.5g IV q6 h or polymyxin B 1.5-2.5
mg/kg IV q24 h in 2 divided doses

Candida species, confirm
susceptibility testina

liposomal amohotericinB 5 mg/kg IV q24 h

fluconazole 400-800 mg IV/PO q24 h, consider adding
flucytosine 25 mg/kg q6 h

*doi:10.1056/NEJMra1301635

in the management of SEA. SEA is most
commonly due to Staphylococcus aureus
(60-90% of cases) with methicillin-resistant S. aureus (MRSA) accounting for a
significant number of infections, up to
40% in some series. 2,5,17,18 Aerobic gramnegative bacilli including Escherichia
Coli, Klebsiella spp. and Pseudomonas
aeruginosa cause SEA in patients with
a history of urinary tract infection and
account for 10-15% of cases. Other
pathogens causing SEA include aerobic
and anaerobic Streptococcus spp.,
Enterococcus spp. and coagulasenegative staphylococci with the latter
associated with spinal procedures such as
the placement of catheters for analgesia,

steroid injections, and surgery. Candida
spp. are also associated with spinal
instrumentation. 5-10% of infections may
be polymicrobic. Atypical pathogens
including Brucella species, mycobacteria
(tuberculous and non-tuberculous) and
fungi can be seen in endemic regions or
immunocompromised hosts.5,17,18 Environmental organisms, for example, the
fungus Exerohilum rostratum that was
responsible for a multi-state outbreak of
spinal infections associated with steroid
injections, have been reported with spine
innoculation. 31 Table 2 summarizes the
microbiology of SEA.
An intraoperative or image guided

sample of the infected fluid should be
obtained and sent for culture. Cultures
for mycobacteria and fungi and serology
for Brucella should be sent if epidemiologic or host risk factors are suggestive
of atypical infection. 2,32 As noted, blood
cultures should be obtained and may be
positive in up to 60% of cases.10,17,27

Management
Prompt surgical decompression and
abscess drainage is indicated in most
cases of SEA to minimize neurologic
injury and for control of sepsis. If there
are focal neurologic changes, surgical
debridement should be performed
urgently.5,7,10,33 Over the past decade,
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conservative management with antibiotics alone has become more common in
patients without neurologic deficits who
have an established causative pathogen
confirmed either with an image guided
aspiration culture or a blood culture
growing a virulent pathogen such as
S. aureus. The rate of failure with this
conservative approach, however, is
estimated to be 30-40% therefore necessitating close monitoring.7,34,35 Of note,
while paraspinal and psoas abscesses and
intradiscal spaces are routinely aspirated
for microbiologic diagnosis, aspiration
and/or drainage of SEA under CT guidance is a technical challenge and only
dorsally located SEA without advanced
bone destruction on MRI qualify for
percutaneous drainage attempt.36
As noted in the 2015 Infectious Diseases
Society of America guidelines for
Native Vertebral Osteomyelitis, empiric
antimicrobial therapy should be withheld until after cultures from blood
and other possible sources of infection
have been obtained except in cases of
sepsis or neurologic deficit. 29 Empiric
antimicrobial therapy should include
coverage of staphylococci (including
MRSA), streptococci and gram-negative
pathogens. While the majority of cases
of SEA are caused by gram-positive
bacteria and therefore empiric coverage
for gram-negative organisms may not be
necessary in all cases, it is recommended
and often implemented. 5,18,29 Vancomycin plus an third or fourth generation
cephalosporin or carbapenem (Ceftazidime, Cefepime or Meropenem) is
considered first line therapy with
alternative coverage for gram-positive
organisms including Daptomycin or
Linezolid, and alternative coverage for
gram-negative organisms including
Azactam or Ciprofloxacin.11,29,32
Once a pathogen is identified, a course
of targeted parental or highly bioavailable
oral antibiotic therapy is recommended.
(Table 3) While parenteral antibiotic
therapy is typically preferred, especially
in treating staphylococcal infection, a
recently published randomized, noninferiority trial found no difference in the
treatment of a variety of bone infections
including 39 cases of spinal infection
some of whom had SEA, between standard parenteral therapy and an early

12
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switch (within 7 days) to oral antibiotic
therapy.42 Any patient in whom there is a
concern for meningitis should be treated
with parenteral therapy dosed for CNS
penetration for at least 2 weeks.43
Recommendations for the duration of
therapy for SEA range from 4 weeks to
3-6 months depending on many factors
including the concurrent presence of
endocarditis, vertebral osteomyelitis
and/or retained spinal hardware.5,29,32,37
Vertebral osteomyelitis commonly
occurs with SEA and is usually treated
with at least 6 weeks of antibiotic
therapy.37–39 Few randomized controlled
trials(RCT) specifically focusing on the
duration of antimicrobial therapy for SEA
and/or vertebral osteomyelitis are available. An open-label, non-inferiority, RCT
of 359 patients compared 6 weeks of
antibiotic therapy to 12 weeks in patients
with pyogenic vertebral osteomyelitis
finding no difference in cure rate at 1
year.40 Information on outcomes with
different antimicrobial regimens and
durations is often derived from observational studies.14,37,41
Some patients may be at higher risk for
relapsed SEA and/or vertebral osteomyelitis including those with undrained
paravertebral or psoas abscess, concomitant endocarditis, MRSA infection,
IVDU, end-stage renal disease, or those
with local spinal wound infection.41,44
In cases of infection in patients at risk
for relapse or related to retained spinal
implants extension of antimicrobial
therapy (>8 weeks) can be considered.
The optimal duration of sequential oral
antibiotic suppression in spinal implant
infection has not been established but
has been shown to decrease the risk of
relapse especially in early-onset infections (<1 month from fusion surgery). In
delayed onset SEA infections associated
with vertebral osteomyelitis, removal of
hardware is associated with improved
outcomes.12,39,45
Patients with SEA should be followed
to ensure response to therapy. A 25%
improvement in ESR and CRP at 4 weeks
of therapy in combination with improved
clinical assessment should be anticipated. A failure of CRP levels to decline
can be a poor prognostic marker.16 End
of treatment imaging is not routinely
recommended although a poor clinical

response to therapy merits repeat MRI
imaging and surgical evaluation.5,18,46

Outcome
The most important predicting factor
for neurologic outcome in SEA is the
patient’s neurologic condition prior
to surgical decompression. Patients
presenting with stage III or IV infection
show the worst recovery rate.4,5,18,47
An outcome of stable or improved
neurologic function in comparison to
the preoperative status is anticipated.
Patients presenting with paralysis for up
to 24-36 hours are expected to regain
some neurologic function after surgery
and this has been correlated with the
rapidity of surgical intervention (within
24 hours). 34,47 Patients may continue
to regain neurologic function and will
benefit from rehabilitation through the
first year after treatment. 34,44
Mortality associated with SEA has
declined significantly with the availability
of advanced cross-sectional imaging,
expanded surgical techniques and effective antibiotic therapy.7 Death usually
results from severe sepsis. Approximately
5-7% of patients with SEA do not survive
in the hospital and 90-day mortality is
estimated at 13%.4,7,48 The best outcomes
in the management of SEA are achieved
with multidisciplinary care.

INTRACRANIAL EPIDURAL
ABSCESS
Epidemiology
The incidence of intracranial epidural
abscess (ICEA) and its related mortality
have decreased since the introduction
of antimicrobial therapy. As ICEA can
cross the dura via the emissary veins an
accompanying subdural empyema is
often present. 2,49

Pathophysiology
Intracranial epidural abscess (ICEA) can
occur following trauma or after neurosurgery including craniotomy, transnasal
or transmastoid procedures. Subdural
empyema can also result from direct infection of the subdural space during these
procedures.2,3 ICEA may also develop as
a complication of sinusitis, otitis media
or mastoiditis and this route of infection
is more common in children and young
adults. Valveless, bidirectional blood flow
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between the frontal sinus mucosa and
dural venous drainage is more common
in children given their highly vascular
diploic bone. Drainage empties into the
superior sagittal sinus, increasing the risk
of subdural extension.49,50 While longitudinal spread is common in SEA, ICEA
without subdural empyema is usually a
localized, slowly expanding lesion that
rarely extends into the spinal column given
the tight adherence of the dura around the
foramen magnum.50

images. 55 Gadolinium enhancement
helps to differentiate infected fluid from
hematoma or sterile collections that can
be seen after trauma or neurosurgery.
The presence of subdural empyema, brain
abscess or other pathology can also be
assessed with MRI. Of note, ICEA can cross
the midline of the brain which subdural
empyema typically does not.2,3,50,55 CT
scan is less sensitive although can be
used to assess bone and may detect a low
attenuation extra-axial mass.3

Clinical Presentation

Microbiology

Presentation includes fever and headache
with variation in time to presentation.
Concern for sinusitis and otitis media
at presentation may distract from the
appropriate diagnosis of ICEA. Periorbital
cellulitis and frontal edema are commonly
seen.2,3,51 ICEA without subdural empyema
may present with insidious onset as the
space between the dura and cranium is
contained, limiting abscess expansion
and delaying the development of focal
neurologic changes.2 If a cranial subdural
empyema is also present, however,
deeper extension of the infection may
lead to more rapid neurologic findings.
Epidural abscess after neurosurgery can
present with rapid progression given the
risk of subdural involvement.3,16 With or
without a subdural empyema, ICEA will
eventually lead to neurologic changes
with possible seizures as well as signs of
increased intracranial pressure including
papilledema.2,3,51 Gradenigo syndrome,
unilateral facial pain and weakness with
involvement of cranial nerves V and VI, can
develop in patients with otitis media and/
or mastoiditis as ICEA extends along the
temporal bone.2,52 Both cranial epidural
abscess and subdural empyema can be
complicated by meningitis, cortical venous
thrombosis and brain abscess.53,54

Common causative pathogens in ICEA
arising after neurosurgery include Staphylococcus aureus, coagulase-negative
staphylococci and gram-negative bacilli.
Infection arising from the paranasal
sinuses or ear is typically caused by
aerobic and anaerobic Streptococcus
spp., anaerobic gram-negative bacilli
including Bacteroides spp., and S. aureus.
While no one organism predominates in
this setting, Streptococcus anginosus
is common. Infection may be polymicrobic. Pseudomonas aeruginosa
infection can arise from otitis media and
fungal infection can arise from chronic
sinusitis.3,50

Diagnosis
Laboratory testing
Laboratory testing in evaluation for ICEA is
non-specific. Leukocytosis may be present.

Imaging Studies
MRI with gadolinium enhancement is the
imaging study of choice in evaluation for
ICEA. An area of diminished intensity is
seen on (Figure 1a) T1 weighted images
with hyperintense patterns and pachymeningeal enhancement on T2 weighted

Management
Given the risk of progression and neurologic deterioration in ICEA, surgical
intervention should be undertaken at
the earliest sign of worsened neurologic status. Combined neurosurgical
and otolaryngologic approaches may
be needed. Open or minimally invasive
craniotomy for drainage of ICEA are
options depending on the location and
degree of bone involvement. Single burr
hole drainage may be associated with
recurrence. Cranialization of the frontal
sinus may be indicated in patients with
ICEA secondary to frontal sinusitis. 3,56
Patients presenting with a small ICEA
can be treated with antimicrobial
therapy with close observation and serial
imaging to monitor response. Empiric
antimicrobial therapy should target
the anticipated pathogens causing
ICEA including aerobic and anaerobic
cocci and bacilli with adequate central
nervous system penetration. 3,50,51 Antimicrobial therapy should be tailored
based on available microbiologic
testing of abscess fluid with confirmation of antibiotic susceptibilities (Table 3).

Treatment duration for ICEA has not been
established. Extended duration is typically preferred and can be extrapolated
from the treatment of brain abscess
with courses of 4-6 weeks often used
including at least 2 weeks of parenteral
therapy.43,50,57

Outcome
The availability of antimicrobial therapy and
advances in neuroimaging have decreased
morbidity and mortality from ICEA. Poor
prognosis is associated with diagnostic
delay in patients presenting with vague
symptoms as well as brain herniation.2,3
The absence of severe neurologic deficits on presentation, minimal co-morbid
conditions and young age are associated
with improved outcomes.
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